Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, M2951; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 42
States / cities: Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more

Conditions: Ischemic Stroke; Ischemic Attack, Transient
Interventions: Milvexian, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 12,523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 127
States / cities: Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more

Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions: TTI-101; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Hereditary Angioedema
Interventions: KVD900 600 mg, KVD900 300 mg; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more

Conditions: Anemia, Iron Deficiency (Without Anemia), Iron Absorption
Interventions: marine-based heme iron; Dietary Supplement
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 21 Years to 42 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Asthma
Interventions: Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 9 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 4 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia
Interventions: FLX925; Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Crohn Disease
Interventions: Lactulose/Rhamnose solution, MB-102; Drug
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dermatomyositis
Interventions: Brepocitinib, Placebo; Drug
Lead sponsor: Priovant Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 33 more

Conditions: Allergy, Asthma
Interventions: Glycerinated German cockroach allergenic extract, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
Interventions: The Bridge; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Interventions: P1446A-05, Vemurafenib (Zelboraf®); Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: South San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 1 more

Conditions: Arrhythmias, Cardiac, Atrial Fibrillation
Interventions: Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation; Drug
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Oral Cancer
Interventions: Deep UV-M and AI Cytology Triage; Device
Lead sponsor: Anh Le; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer
Interventions: Metagenomic sequencing, Metabolic analysis; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Malignant Melanoma
Interventions: vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Tampa, Florida + 7 more

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Cytarabine, Milademetan Tosylate, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Interventions: nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 10
States / cities: Loma Linda, California • Palo Alto, California • Orlando, Florida + 7 more

Conditions: Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions: Infigratinib; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 3 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Papulopustular Rosacea
Interventions: DFD-29, Doxycycline, Placebo; Drug
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more

Conditions: Pulmonary Hypertension Secondary, Heart Failure
Interventions: Sodium Nitrite, Placebo Oral Capsule; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Ruxolitinib 25 mg, Dexamethasone 40 mg; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Highland, California • Boynton Beach, Florida • New York, New York

Search by objective public record fields.

A Phase II Study of M2951 in SLE

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)

First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma

Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Feasibility and Safety of IV Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy

Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage

Microbiome in Head and Neck Squamous Cell Carcinoma

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma